Microbix Biosystems Inc. · TSX:MBX
Microbix Biosystems — Investor Presentation (September 2026)
24 slides from Microbix Biosystems's investor presentation, September 2026
Slide 1: Microbix Presentation: Advancing Global Health By Supporting Next-Generation Diagnostics
TSX: MBX | OTCQX: MBXBF Microbix Presentation Advancing Global Health By Supporting Next-Generation Diagnostics Autumn 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements about trends and objectives. Risks and uncertainties relating to such statements could cause actual outcomes to differ materially. Such risks include, among others, those related to operations, customers or markets, gro
Slide 3: Microbix – Supporting Next-Generation Diagnostics
Microbix – Supporting Next-Generation Diagnostics Established Global Addition of Higher-Value, Stabilized Base, Diagnostics Supplier Faster-Growing QAPs Positioned for Growth • 30+ year track record supplying • Expanding quality assessment & • F2026 expected revenue of $16-17M antigens to 100+ diagn
Slide 4: Financials – Microbix Capital Structure
Financials – Microbix Capital Structure TSX: MBX • OTCQX: MBXBF Analyst Coverage Current Price $0.305 (2026-9-22) Shares Outstanding (Basic) 137.2M** (Fully Diluted) 168.5M** David Martin 52 Week High $0.325 Target Price: $0.40 52 Week Low $0.21 Market Cap $41.8M Avg. Daily Volume ~50K (3 month) Cas
Slide 5: Experienced Leadership Team with Deep Diagnostics & Commercial Expertise
Experienced Leadership Team with Deep Diagnostics & Commercial Expertise Cameron L. Groome Jim Currie, CPA Ken Hughes, Ph.D. CEO, President, and Director Chief Financial Officer Chief Operating Officer • Has served on the MBX BoD and AC since • Joined MBX as CFO in 2016 after several • Executive and
Slide 6: Microbix Board of Directors
Microbix Board of Directors Experienced Board with Deep Healthcare, Pharma, and Governance Expertise Martin Marino Dr. Peter M. Blecher Mark A. Cochran, Ph.D. Board Chairman Director HRGC Chair • Mr. Marino has 30+ years of experience in • Dr. Blecher, a longtime ER physician and • Dr. Cochran was E
Slide 7: Two Complementary Product Lines Supporting Global Diagnostics
Two Complementary Product Lines Supporting Global Diagnostics Established base business with growing exposure to higher-value quality controls Antigen Sales - established base business (C$ 1,000s) We grow, purify, and inactivate many $16,000 bacteria and viruses to make “Antigens,” $14,000 as critic
Slide 8: Test Ingredients – Antigens
Test Ingredients – Antigens Established Core Business with Deep Customer Integration Grows, purifies, and inactivates native bacteria and viruses for use as antigens for more than 100 leading international diagnostic companies. Microbix provides antigens on a large scale for major international diag
Slide 9: Test Controls – Quality Assessment Products (QAPs)
Test Controls – Quality Assessment Products (QAPs ) A higher-value, recurring segment of the diagnostics market What QAPs Actually Do: Simulate real patient samples (e.g., as liquids, swabs, or tissue) to validate Dx assay performance. This is used across many QMS purposes, including for certifying
Slide 10: Microbix is a Trusted Partner Across The Global Diagnostics Ecosystem
Microbix is a Trusted Partner Across The Global Diagnostics Ecosystem Microbix has been supporting international test makers for decades – its Antigens forming the heart of millions of Immunoassays. It has over 100 such customers, many ordering large amounts of product. Over recent years, Microbix h
Slide 11: Where Microbix Products are Used
Where Microbix Products are Used Our Ingredients (Antigens) and Medical Devices (QAPs) are in use around the world. Microbix products are available in more than 30 countries, directly or via partners. World Map of Antigen and QAPs Distribution TSX: MBX | OTCQX: MBXBF 11
Slide 12: Ensuring Confidence in Diagnostic Tests
Ensuring Confidence in Diagnostic Tests Makers, Regulators, Users, & Payors Need Proof They Work Our Products Help Ensure that Tests Microbix makes essential products that enable diagnostic Actually Work. This is Critical for tests to be made and sold. Many next-generation Dx assays need Microbix pr
Slide 13: Kinlytic® – FDA-Approved, Fully Funded Drug with a Defined Path to Market
Kinlytic® – FDA-Approved, Fully Funded Drug with a Defined Path to Market Microbix owns the BLA of a well-established thrombolytic drug. Partnered with Sequel Pharma, LLC for re-launch of cell-culture derived LMW urokinase Kinlytic® Urokinase Microbix’s deep expertise in cell-culturing led to its se
Slide 14: Kinlytic® – An FDA-Approved Clot-Buster Drug
Kinlytic® – An FDA-Approved Clot-Buster Drug Refined project scope to first address the Sequel Pharma, LLC has secured Catheter Clearance Indication & its 100% funding of ~US$ 35M to fully U.S. market as initial value-driver underwrite total project cost & risk Major international CDMOs are now upda
Slide 15: Scaled Manufacturing & Regulatory Infrastructure to Support Growth
Scaled Manufacturing & Regulatory Infrastructure to Support Growth Significant capacity in place to support revenue expansion without major incremental capital We Have Built Both Capabilities and Capacity To Secure New Product & Customer Opportunities Built for Scale: • 3 fully operational facilitie
Slide 16: Scaled Manufacturing Capacity Ready for Growth
Scaled Manufacturing Capacity Ready for Growth We Have Built Both Capabilities and Capacity To Secure New Product & Customer Opportunities QAP Production Capacity • Liquid vial format: ~150,000 units/month capacity • Dried swab format: ~200,000 units/month capacity Automation & Efficiency • Semi-aut
Slide 17: Operations - Expanding Product Line & Revenue
Operations - Expanding Product Line & Revenue Microbix’s product line is rapidly expanding, as is our base of customers. Just in the past months… January 2026 – Commercialized recombinant SARS-CoV-2 nucleocapsid antigen for QAPs and inclusion in Microbix catalogue. February 2026 – In Finland, presen
Slide 18: Microbix – The Past 10 Years at a Glance
Microbix – The Past 10 Years at a Glance 2017 – 2026 2017 2018 2019 2020 2021 New CEO & Recapitalization Facility Upgrades 2nd Site Leased for QAPs COVID QAP Launched (March 2020) Viral Transport Medium Creation Reinvestment into sales-driven businesses Material upgrades to 265 Watline To expand mfg
Slide 19: Financials – The Past Several Years
Financials – The Past Several Years Revenues, Current Ratio1, Net Earnings, and EBITDA1 Have Repurchased (& cancelled) over 12.5 Million Shares REVENUE CURRENT RATIO1 30,000,000 25,000,000 9 8 20,000,000 7 6 15,000,000 5 10,000,000 4 3 5,000,000 2 1 0 0 2021 2022 2023 2024 2025 2026 2021 2022 2023 2
Slide 20: Clear Path to Revenue Growth and Product Mix Expansion
Clear Path to Revenue Growth and Product Mix Expansion Leveraging existing relationships, expanding product adoption, and entering new markets 1. Expand Within Existing Customers 2. Add New High-Value Customers • Cross-sell QAPs into >100 existing • Target diagnostic Cos. with >$1M diagnostic custom
Slide 21: Key Takeaways about Microbix
Key Takeaways about Microbix 1. Established Diagnostics Platform with Global Customers Microbix has become a “go-to” partner regarding next-generation diagnostic tests. Its • Trusted supplier to 100+ diagnostic companies, EQA providers, and labs QAPs are often essential for approval/adoption • Embed
Slide 22: Thank You
TSX: MBX | OTCQX: MBXBF Thank You Cameron Groome CEO, President, and Director cameron.groome@microbix.com TSX: MBX | OTCQX: MBXBF
Slide 23: Appendix regarding non-GAAP Financial Measures
Appendix regarding non-GAAP Financial Measures This appendix provides important context concerning the non-GAAP financial measure “EBITDA” referenced on slides 3 and 19 earlier herein. Non-GAAP (non-IFRS) Measures Discussion Cutting-Edge In addition to disclosing Capabilities detailed operating & Re
Slide 24: Appendix regarding non-GAAP Financial Measures (Continued)
Appendix regarding non-GAAP Financial Measures (Continued) Reconciliation of Non-GAAP (non-IFRS) Measure Cutting-Edge Capabilities & Real Revenue Growth Opportunities Both Dx & Rx Projects Self-Funding with Great Prospects Expanding Earnings Potential to Drive Share Price Appreciation TSX: MBX | OTC
Microbix Biosystems — Investor Presentation (September 2026) on 6ix